gsidgsidgsid
Welcome to the Global Solutions For Infectious Diseases Website
GSID Home Page
About Us
Our Programs
Support GSID
News & Publications
Contact Us
header

Concept Sheets for Specimen Sample and Data Requests

GSID is interested in collaborating with HIV vaccine researchers. We provide a unique opportunity to obtain certain serological samples, including serum and plasma, and related viral sequences contained in the database related to the AIDSVAX® clinical trials. In addition, the specimen repository also contains samples from uninfected subjects. Interested investigators should submit a written concept sheet outlining the information shown directly below and submitting it via email to GSID.

Please include the following information in your concept sheet and sample request:
• Name of requesting organization
• Name of principal investigator
• Investigator contact information
• Type of serological material: serum or plasma
• Total quantity of material requested
• Detailed description of planned experiment methods, including the justification for quantities requested
• Description of experiment objectives
• Please identify your funding source

The specimens are a limited resource; therefore the volumes and the availability of samples may vary by each subject. GSID cannot guarantee that it will be able to fulfill a request to the exact specifications of the scientific investigator, but every effort will be made to accommodate the request. However, GSID reserves the right to adjust the request based upon availability of material and/or make recommendations to satisfy the volume requirements of the planned experiments.

There are significant costs associated with maintaining our specimen repository, therefore we charge a handling fee to cover the cost of our time to establish the Material Transfer Agreement (MTA); and to identify, pull and prepare samples for shipping.

Please note that any scientific publication or presentation resulting from the use of the materials provided by GSID must contain an attribution to GSID as the provider. GSID also requires that when specimens or data from the VAX003 trial conducted in Thailand that the volunteers of the VAX003 trial and the primary sponsor, the Bangkok Vaccine Evaluation Group, also be acknowledged. Finally, GSID requires that it be able to review and comment on the publication at least 30 days prior to finalization.

A list of our AIDSVAX research collaborators is available here.


Additional Resources




 

 


GSID to support four new AIDSVAX® B/E clinical trials in 2017
[more]